The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 vaccine as a post-approval commitment, a source familiar with the matter told CNN.

A new randomized study could cost Novavax tens of millions of dollars, vaccine experts say

The company says its vaccine is on track for full approval, following delay. Novavax shares soared following the announcement.